| Modeling PNPLA3‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells SG Tilson, CM Morell, AS Lenaerts, SB Park, Z Hu, B Jenkins, A Koulman, ... Hepatology 74 (6), 2998-3017, 2021 | 43 | 2021 |
| Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals S Seronello, J Montanez, K Presleigh, M Barlow, SB Park, J Choi PLoS One 6 (11), e27436, 2011 | 43 | 2011 |
| Hepatitis C virus frameshift/alternate reading frame protein suppresses interferon responses mediated by pattern recognition receptor retinoic-acid-inducible gene-I SB Park, S Seronello, W Mayer, DM Ojcius Plos one 11 (7), e0158419, 2016 | 26 | 2016 |
| Chlorcyclizine inhibits viral fusion of hepatitis C virus entry by directly targeting HCV envelope glycoprotein 1 Z Hu, A Rolt, X Hu, CD Ma, DJ Le, SB Park, M Houghton, N Southall, ... Cell chemical biology 27 (7), 780-792. e5, 2020 | 20 | 2020 |
| TM6SF2 promotes lipidation and secretion of hepatitis C virus in infected hepatocytes A Boyer, SB Park, YS de Boer, Q Li, TJ Liang Gastroenterology 155 (6), 1923-1935. e8, 2018 | 15 | 2018 |
| SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype SB Park, M Khan, SC Chiliveri, X Hu, P Irvin, M Leek, A Grieshaber, Z Hu, ... Communications biology 6 (1), 556, 2023 | 13 | 2023 |
| Genetically edited hepatic cells expressing the NTCP-S267F variant are resistant to hepatitis B virus infection T Uchida, SB Park, T Inuzuka, M Zhang, JN Allen, K Chayama, TJ Liang Molecular Therapy-Methods & Clinical Development 23, 597-605, 2021 | 12 | 2021 |
| A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells SB Park, T Uchida, S Tilson, Z Hu, CD Ma, M Leek, M Eichner, SG Hong, ... Molecular Therapy-Nucleic Acids 28, 656-669, 2022 | 11 | 2022 |
| Targeting the fusion process of SARS-CoV-2 infection by small molecule inhibitors SB Park, P Irvin, Z Hu, M Khan, X Hu, Q Zeng, C Chen, M Xu, M Leek, ... MBio 13 (1), e03238-21, 2022 | 11 | 2022 |
| Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion CD Ma, M Imamura, DC Talley, A Rolt, X Xu, AQ Wang, D Le, T Uchida, ... Nature microbiology 5 (12), 1532-1541, 2020 | 10 | 2020 |
| Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle SB Park, A Boyer, Z Hu, D Le, TJ Liang Antiviral Therapy 24 (5), 371-381, 2019 | 5 | 2019 |
| Discovery and optimization of a 4-aminopiperidine scaffold for inhibition of hepatitis C virus assembly A Rolt, DC Talley, SB Park, Z Hu, A Dulcey, C Ma, P Irvin, M Leek, ... Journal of medicinal chemistry 64 (13), 9431-9443, 2021 | 4 | 2021 |
| ETHANOL, OXIDATIVE STRESS, AND HCV: DIRECT EFFECTS ON VIRAL REPLICATION AND MUTATION J Choi, S Seronello, J Montanez, K Presleigh, T Vo, SB Park, M Barlow ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 36, 339A-339A, 2012 | | 2012 |
